20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- The FDA has approved Axsome Therapeutics Inc's (NASDAQ:AXSM) Auvelity (dextromethorphan HBr -bupropion HCl) extended-release tablets for major depressive disorder (MDD) in adults.
- Auvelity is the first and only rapid-acting oral medicine approved for the treatment of MDD with the labeling of statistically significant antidepressant efficacy compared to placebo starting at one week.
- Related: Axsome Therapeutics Rallies 40% On FDA Product Label Proposal, But Analyst Remains Skeptical.
- The rapid antidepressant effects of Auvelity have been sustained at all subsequent time points.
- Auvelity is the first and only oral N-methyl D-aspartate (NMDA) receptor antagonist approved for treating MDD.
- Axsome anticipates Auvelity to be commercially available in the U.S. in Q4 of 2022.
- The product is protected by a robust patent estate extending to at least 2037-2040 and was studied in a comprehensive clinical program that included more than 1,100 depression patients.
- Price Action: AXSM shares are up 26.10% at $53.50 during the premarket session on the last check Friday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!